Day Trader తెలుగు

Photo

US FDA releases warning letter details for Aurobindo #Pharma’s New Jersey unit. The regulator says Methods, facilities, manufacturing, processing do not conform to Current Good Manufacturing Practice (CGMP) & strongly recommends engaging a consultant